Broken String Biosciences is a genomics company with a mission to advance the next generation of more precise, safe, and effective cell and gene therapies through its cutting-edge technology platforms.
The Company’s core technology, INDUCE-seq®, is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify off-target genetic edits, and evaluate the associated genetic outcomes. The platform technology provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.
Broken String Biosciences was spun out of Cardiff University in 2020 and completed a six-month residency at the Illumina Accelerator in Cambridge, UK. The Company has raised financing of $20m USD to date from venture capital investors.
www.brokenstringbio.com
